Northern Trust Corp Madrigal Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

$586 Billion
Q2 2024

A detailed history of Northern Trust Corp transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 131,445 shares of MDGL stock, worth $28.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

131,445

Previous 131,358 0.07%

Holding current value

$28.6 Million

Previous $35.1 Million 4.98%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$193.33 - $291.99 $16,819 - $25,403	87 Added 0.07%	131,445 $36.8 Million
Q1 2024 May 14, 2024	SELL	$171.37 - $283.23 $573,746 - $948,254	-3,348 Reduced 2.49%	131,358 $35.1 Million
Q4 2023 Feb 13, 2024	BUY	$120.4 - $237.13 $1.33 Million - $2.62 Million	11,057 Added 8.94%	134,706 $31.2 Million
Q3 2023 Nov 13, 2023	BUY	$146.04 - $225.78 $153,342 - $237,069	1,050 Added 0.86%	123,649 $18.1 Million
Q2 2023 Aug 11, 2023	BUY	$203.88 - $312.0 $1.86 Million - $2.84 Million	9,114 Added 8.03%	122,599 $28.3 Million
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $460,271 - $611,703	1,992 Added 1.79%	113,485 $27.5 Million
Q4 2022 Feb 13, 2023	SELL	$58.39 - $296.54 $111,641 - $566,984	-1,912 Reduced 1.69%	111,493 $32.4 Million
Q3 2022 Nov 14, 2022	SELL	$60.57 - $79.51 $96,306 - $126,420	-1,590 Reduced 1.38%	113,405 $7.37 Million
Q2 2022 Aug 12, 2022	BUY	$58.04 - $100.2 $208,537 - $360,018	3,593 Added 3.23%	114,995 $8.23 Million
Q1 2022 May 13, 2022	SELL	$55.89 - $101.89 $308,959 - $563,247	-5,528 Reduced 4.73%	111,402 $10.9 Million
Q4 2021 Feb 08, 2022	BUY	$72.34 - $95.09 $353,236 - $464,324	4,883 Added 4.36%	116,930 $9.91 Million
Q3 2021 Nov 15, 2021	SELL	$78.35 - $105.02 $220,555 - $295,631	-2,815 Reduced 2.45%	112,047 $8.94 Million
Q2 2021 Aug 13, 2021	BUY	$97.2 - $137.59 $1.39 Million - $1.97 Million	14,284 Added 14.2%	114,862 $11.2 Million
Q1 2021 May 12, 2021	SELL	$108.54 - $125.2 $373,920 - $431,314	-3,445 Reduced 3.31%	100,578 $11.8 Million
Q4 2020 Feb 11, 2021	SELL	$110.06 - $133.7 $204,381 - $248,280	-1,857 Reduced 1.75%	104,023 $11.6 Million
Q3 2020 Nov 16, 2020	SELL	$99.78 - $124.21 $721,209 - $897,789	-7,228 Reduced 6.39%	105,880 $12.6 Million
Q2 2020 Aug 14, 2020	BUY	$60.13 - $125.71 $116,171 - $242,871	1,932 Added 1.74%	113,108 $12.8 Million
Q1 2020 May 14, 2020	BUY	$66.76 - $93.49 $1.03 Million - $1.44 Million	15,451 Added 16.14%	111,176 $7.42 Million
Q4 2019 Feb 14, 2020	SELL	$84.28 - $118.5 $755,317 - $1.06 Million	-8,962 Reduced 8.56%	95,725 $8.72 Million
Q3 2019 Nov 13, 2019	BUY	$84.4 - $106.53 $530,032 - $669,008	6,280 Added 6.38%	104,687 $9.03 Million
Q2 2019 Aug 13, 2019	BUY	$91.13 - $142.5 $194,653 - $304,380	2,136 Added 2.22%	98,407 $10.3 Million
Q1 2019 May 13, 2019	BUY	$103.48 - $143.84 $129,039 - $179,368	1,247 Added 1.31%	96,271 $12.1 Million
Q4 2018 Feb 12, 2019	SELL	$94.77 - $215.54 $739,585 - $1.68 Million	-7,804 Reduced 7.59%	95,024 $10.7 Million
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $2.52 Million - $3.65 Million	12,165 Added 13.42%	102,828 $22 Million
Q2 2018 Sep 18, 2018	SELL	$101.55 - $313.9 $83,271 - $257,397	-820 Reduced 0.9%	90,663 $25.4 Million
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $1.81 Million - $5.6 Million	17,843 Added 24.23%	91,483 $25.6 Million
Q1 2018 May 09, 2018	BUY	$93.35 - $149.04 $783,486 - $1.25 Million	8,393 Added 12.86%	73,640 $8.6 Million
Q4 2017 Feb 14, 2018	BUY	$39.35 - $97.37 $489,946 - $1.21 Million	12,451 Added 23.58%	65,247 $5.99 Million
Q3 2017 Nov 13, 2017	BUY	$15.48 - $46.19 $817,282 - $2.44 Million	52,796	52,796 $2.37 Million

Others Institutions Holding MDGL

# of Institutions

297

Shares Held

21.9M

Call Options Held

757K

Put Options Held

370K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $3.72B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Madrigal Pharmaceuticals, Inc. Transaction History